Combined Administration of (R)-Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Induces Rapid and Sustained Effects in the CUMS Model of Depression via a TrkB/BDNF-Dependent Mechanism
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Ketamine is an effective, rapid-acting antidepressant drug (RAAD), but it induces side effects. To overcome these challenges, attempts have been made to use safer enantiomer ((R)-ketamine) or mGlu2/3 receptor antagonists, which induce ketamine-like effects and enhance its action. Here, we propose combining these two strategies to investigate the antidepressant-like effects of low doses of two ketamine enantiomers in combination with a low dose of the mGlu2/3 receptor antagonist LY341495. Rapid and sustained antidepressant-like effects were assessed in C57BL/6J mice using the tail suspension test (TST) and the chronic unpredictable mild stress (CUMS) model of depression in stress-naïve mice. ELISA was used to measure BDNF levels. In the TST, low doses of both (S)-ketamine and (R)-ketamine were potentiated by a subeffective dose of LY341495. However, in the CUMS model, only (R)-ketamine was able to induce long-lasting anti-apathetic and anti-anhedonic effects when coadministered with low-dose LY341495. The mechanism of this drug combination was dependent on BDNF and AMPA receptor activity. ELISA results suggest that the hippocampus might be the site of this action. MGlu2/3 receptor antagonists, in combination with (R)-ketamine, may serve as potential RAADs, with a high efficiency and low risk of side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Co-administration of ketamine and an mGluR2/3 antagonist also sustained antidepressant-like responses in another animal model [197], which further supports mGluR2/3 antagonists as effective adjunctive therapies.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [197]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 4×
“This AMPA receptor-mediated synaptic potentiation has been proposed to play a critical role in the rapid antidepressant effect of ketamine [21,22,38].”
BackgroundResultInfluentialCryan, J. F., Mombereau, C., & Vassout, A. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.009 · Cited by 1,674
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160 · cited 1×
“In this model, we analyzed three parameters that reflect the core symptoms of depression: reduced grooming time in the splash test, which reflects apathy [29]; decreased sucrose preference, which indicates anhedonia [30]; and increased immobility time in the TST, which relates to helplessness [24].”
MethodThe chronic mild stress (CMS) model of depression: History, evaluation and usage
Willner, P. (2017) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.08.002 · Cited by 959
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
Castrén, E., & Monteggia, L. M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.008 · Cited by 540
Cazorla, M., Prémont, J., Mann, A., Girard, N., Kellendonk, C., & Rognan, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43992 · Cited by 392
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385
BDNF release is required for the behavioral actions of ketamine
Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., & Duman, R. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu033 · Cited by 368
Acute suppression of spontaneous neurotransmission drives synaptic potentiation
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., & Kavalali, E. T. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4998-12.2013 · Cited by 283 · cited 2×
“This AMPA receptor-mediated synaptic potentiation has been proposed to play a critical role in the rapid antidepressant effect of ketamine [21,22,38].”
BackgroundEbert, B., Mikkelsen, S., Thorkildsen, C., & Borgbjerg, F. M. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01116-3 · Cited by 270
Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Yang, C., Ren, Q., Qu, Y., Zhang, J.-C., Ma, M., Dong, C., & Hashimoto, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.016 · Cited by 250
Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine
Monleon, S., Parra, A., Simon, V. M., Brain, P. F., D'Aquila, P., & Willner, P. (1995) · Psychopharmacology · doi:10.1007/bf02246218 · Cited by 233
Measuring behavior in mice with chronic stress depression paradigm
Strekalova, T., & Steinbusch, H. W. M. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.12.014 · Cited by 207
Chang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.-M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.008 · Cited by 176
Lepack, A. E., Bang, E., Lee, B., Dwyer, J. M., & Duman, R. S. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.011 · Cited by 174 · cited 5×
“This effect may occur via inhibition of GABA interneurons by (R)-ketamine and/or blockade of presynaptic Glu2/3 autoreceptors by LY341495 [11,12], which may finally lead to a synergistic effect.”
BackgroundResultInfluential( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819540116 · Cited by 152 · cited 7×
“These results generally confirm previous data on the mechanisms of the antidepressant-like effects of ketamine and mGlu2/3 antagonists in the TST and the FST when tested separately at similar times after administration [10,12].”
BackgroundResultInfluentialArosio, B., Guerini, F. R., Voshaar, R. C. O., & Aprahamian, I. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.626906 · Cited by 145
Dong, C., Zhang, J.-C., Yao, W., Ren, Q., Ma, M., Yang, C., Chaki, S., & Hashimoto, K. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw089 · Cited by 116
A Synaptic Locus for TrkB Signaling Underlying Ketamine Rapid Antidepressant Action
Lin, P.-Y., Ma, Z. Z., Mahgoub, M., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109513 · Cited by 99
Koike, H., Fukumoto, K., Iijima, M., & Chaki, S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.10.023 · Cited by 98
Ago, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz041 · Cited by 92
Sun, H.-L., Zhou, Z.-Q., Zhang, G.-F., Yang, C., Wang, X.-M., Shen, J.-C., Hashimoto, K., & Yang, J.-J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.21 · Cited by 84
Dwyer, J. M., Lepack, A. E., & Duman, R. S. (2013) · Journal of Molecular Psychiatry · doi:10.1186/2049-9256-1-15 · Cited by 81
Sałat, K., Siwek, A., Starowicz, G., Librowski, T., Nowak, G., Drabik, U., Gajdosz, R., & Popik, P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.037 · Cited by 77
Esketamine is approved in Europe for treating resistant major depressive disorder
Mahase, E. (2019) · BMJ · doi:10.1136/bmj.l7069 · Cited by 67
Papp, M., Gruca, P., Lason-Tyburkiewicz, M., & Willner, P. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000259 · Cited by 63
The translational study of apathy—an ecological approach
Cathomas, F., Hartmann, M. N., Seifritz, E., Pryce, C. R., & Kaiser, S. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00241 · Cited by 61
Fujita, A., Fujita, Y., Pu, Y., Chang, L., & Hashimoto, K. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05346-5 · Cited by 56
Pałucha-Poniewiera, A., Podkowa, K., Rafało-Ulińska, A., Brański, P., & Burnat, G. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000564 · Cited by 56
Self-citationBechtholt, A. J., Smith, K. L., John, C. S., Kang, H., Carlezon, W. A., Cohen, B. M., & Öngür, D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2169-8 · Cited by 51
Tan, Y., Fujita, Y., Qu, Y., Chang, L., Pu, Y., Wang, S., Wang, X., & Hashimoto, K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172839 · Cited by 45
Rafało-Ulińska, A., & Pałucha-Poniewiera, A. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113633 · Cited by 45
Self-citationQu, Y., Shan, J., Wang, S., Chang, L., Pu, Y., Wang, X., Tan, Y., Yamamoto, M. P., & Hashimoto, K. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01208-w · Cited by 44
Podkowa, K., Pochwat, B., Brański, P., Pilc, A., & Pałucha-Poniewiera, A. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4325-7 · Cited by 43
Self-citationPałucha-Poniewiera, A., Podkowa, K., & Rafało-Ulińska, A. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110239 · Cited by 43
Self-citationAgnieszka, P.-P., Karolina, P., & Andrzej, P. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000471 · Cited by 31
Jiang, H., Veldman, E. R., Tiger, M., Ekman, C. J., Lundberg, J., & Svenningsson, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.698633 · Cited by 20
Camargo, A., Dalmagro, A. P., Wolin, I. A. V., Siteneski, A., Zeni, A. L. B., & Rodrigues, A. L. S. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110371 · Cited by 18
Cited by
Pathophysiology and Current Drug Treatments for Post-Stroke Depression: A Review
Frank, D., Gruenbaum, B. F., Zlotnik, A. A., Semyonov, M., Frenkel, A., & Boyko, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315114 · Cited by 174
The antidepressant actions of ketamine and its enantiomers
Johnston, J. N., Henter, I. D., & Zarate, C. A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108431 · Cited by 108
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
cAMP-PKA cascade: An outdated topic for depression?
Gao, F., Yang, S., Wang, J., & Zhu, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113030 · Cited by 87
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
Metadata
- Authors
- Rafało-Ulińska, A., Brański, P., & Pałucha-Poniewiera, A.
- Affiliations
- Maj Institute of Pharmacology (PL)
- Corresponding author
- Pałucha-Poniewiera, Agnieszka
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2022-01-21
- Volume
- 15
- Issue
- 2
- Pages
- 125
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC8879988
- OpenAlex
- W4207049519
- Cited by
- 29
- References
- 45
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 10
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Science Center (2017/27/B/NZ7/01873)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- (R)-ketamine, LY341495, rapid-acting antidepressants, depression, chronic unpredictable mild stress, brain-derived neurotrophic factor, TrkB signaling, AMPA receptors, hippocampus, anhedonia, apathy, combination therapy, ketamine enantiomers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.